Active Biotech publishes prospectus and certain new financial information included in the prospectus - Seite 2

MSEK	31 October 2020
(A) Cash	-
(B) Cash equivalents	28.1
(C) Trading securities	-
(D) Liquidity (A)+(B)+(C)	28.1
(E) Current financial receivables	-
(F) Current bank debt	-
(G) Current portion of non-current debt	1.3
(H) Other current financial debt	-
(I) Other current financial debt (F)+(G)+(H)	1.3
(J) Net current financial indebtedness (I)-(E)-(D)	-26.8
(K) Non-current bank loans	-
(L) Bonds issued	-
(M) Other current financial debt	0.9
(N) Non-current financial indebtedness (K)+(L)+(M)	0.9
(O) Net financial indebtedness (J)+(N)	-25.9

For further information, please contact:
Helén Tuvesson, CEO, [phone], [e-mail]
Hans Kolam, CFO, [phone], [e-mail]

Active Biotech
Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio
refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase I/II clinical program in patients with advanced solid tumors. The small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is advancing to phase II for treatment of non-infectious uveitis during second half of 2021.  Please visit www.activebiotech.com for more information.